{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-25-000004","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.964542+00:00","generated_at":"2026-05-26T02:24:03.922922+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nautilus Biotechnology reports Q4 net loss $17.6M; platform launch delayed to late 2026; headcount cut 16%","bullets":["Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).","Net loss Q4 $17.6M vs $17.0M YoY; FY2024 net loss $70.8M vs $63.7M YoY.","Proteome analysis platform commercial launch now expected late 2026 (previously undisclosed).","Headcount reduced ~16% to extend cash runway; cash $206.3M expected to fund operations through 2027.","Board changes: two directors not standing for re-election; Matthew McIlwain reclassified as Class I director; board size reduced to 7."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-25-000004","json":"https://secwatch.observer/filing/0001808805-25-000004.json","markdown":"https://secwatch.observer/filing/0001808805-25-000004.md","text":"https://secwatch.observer/filing/0001808805-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/naut-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:24:03.922922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38fb08b154","claim":"Michael Altman departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"75b9655f13","claim":"Matthew McIlwain departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"agreed to resign as a Class II director and to stand for election as a Class I director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ed77919d04","claim":"Vijay Pande departed as Director at Nautilus Biotechnology, Inc..","evidence_excerpt":"each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000004/0001808805-25-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}